By Application
Hot products 
-
Mouse Anti-FeLV g27 Recombinant Antibody (1) (CBMAB-V208-1714-FY)
-
Rat Anti-EMCN Recombinant Antibody (28) (CBMAB-E0280-FY)
-
Rabbit Anti-AKT2 (Phosphorylated S474) Recombinant Antibody (V2-556130) (PTM-CBMAB-0605LY)
-
Mouse Anti-DISP2 Monoclonal Antibody (F66A4B1) (CBMAB-1112CQ)
-
Rat Anti-AChR Recombinant Antibody (V2-12500) (CBMAB-0990-CN)
-
Mouse Anti-AZGP1 Recombinant Antibody (CBWJZ-007) (CBMAB-Z0012-WJ)
-
Rabbit Anti-ADRA1A Recombinant Antibody (V2-12532) (CBMAB-1022-CN)
-
Mouse Anti-AMIGO2 Recombinant Antibody (CBYY-C0756) (CBMAB-C2192-YY)
-
Mouse Anti-FN1 Monoclonal Antibody (71) (CBMAB-1241CQ)
-
Mouse Anti-DLL4 Recombinant Antibody (D1090) (CBMAB-D1090-YC)
-
Mouse Anti-CIITA Recombinant Antibody (CBLC160-LY) (CBMAB-C10987-LY)
-
Mouse Anti-ENO2 Recombinant Antibody (H14) (CBMAB-E1341-FY)
-
Mouse Anti-CEMIP Recombinant Antibody (3C12) (CBMAB-K0296-LY)
-
Mouse Anti-ADGRE5 Recombinant Antibody (V2-360335) (CBMAB-C2088-CQ)
-
Rabbit Anti-AP2M1 (Phosphorylated T156) Recombinant Antibody (D4F3) (PTM-CBMAB-0610LY)
-
Mouse Anti-AMOT Recombinant Antibody (CBYC-A564) (CBMAB-A2552-YC)
-
Mouse Anti-C5AR1 Recombinant Antibody (R63) (CBMAB-C9553-LY)
-
Mouse Anti-AP4E1 Recombinant Antibody (32) (CBMAB-A2996-YC)
-
Mouse Anti-ATM Recombinant Antibody (2C1) (CBMAB-A3970-YC)
-
Mouse Anti-ACTG1 Recombinant Antibody (V2-179597) (CBMAB-A0916-YC)
Skin Cancer (SCC)
Fig.1 Squamous cell skin cancer
Squamous-cell skin cancer, also named as cutaneous squamous-cell carcinoma (cSCC), is one of the typical types of skin cancer along with melanoma and basal cell cancer. Normally, it presents as a hard lump with a scaly top but can also deteriorate into an ulcer. Onset is often several months. Squamous-cell skin cancer is more likely to spread to distant areas comparing with basal cell cancer. The greatest risk factor is the high total exposure to ultraviolet radiation from the sun. Squamous cell cancers happening in the ears and lip have high possibilities of local recurrence and distant metastasis (about 20–50%). SCCs represent around 20% of the non-melanoma skin cancers, but on account of their more obvious nature and growth rates, they stands for 90% of all head and neck cancers that are primarily presented. CD10, as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma, has been studied.
Loading...
Compare
